<prompt> CD4 counts should be monitored weekly during therapy with?EfalizumabOnerceptInfliximabAlefacept  <response>: Alefacept is an engineered protein consisting of the CD2-binding poion of leukocyte-function-associated antigen-3 LFA-3 fused to a human IgG1 Fc region hinge, CH1, and CH2, approved for the treatment of plaque psoriasis. It inhibits activation of T-cells by binding to cell surface CD2, inhibiting the normal CD2LFA-3 interaction. Treatment of patients with Alefacept also results in a dose-dependent reduction of the total number of circulating T cells, including those that predominate in psoriatic plaques. Therefore, T-cell counts of patients receiving Alefacept must be monitored, and the drug discontinued if CD4 lymphocyte levels fall below 250 cells L. 